These agents enhance tumor targeting by promoting immune recognition of tumor-specific neoantigens, which are processed into immunogenic peptides that activate cytotoxic CD8+ T lymphocytes capable of eliminating malignant cells [43]. The gene discussed is CD8A; the disease is neoplasm.